このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

タルケタマブ関連の経口毒性の予防治療を評価する研究 (Talisman)

2026年9月24日 更新者:Janssen Research & Development, LLC

タルケタマブ関連の経口毒性に対する予防的介入を評価するための第 2 相非盲検ランダム化研究

The purpose of this study is to identify preventive treatments that can minimize the occurrence, severity, and duration of talquetamab-related taste changes (dysgeusia), during the prophylaxis (preventive) treatment phase, to better characterize the signs or symptoms of talquetamab-related taste changes and to better characterize the signs or symptoms of ramantamig-related taste changes.

調査の概要

研究の種類

介入

入学 (推定)

210

段階

  • フェーズ2

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究場所

    • California
      • San Francisco、California、アメリカ、94143
        • 募集
        • University of California San Francisco
    • Colorado
      • Denver、Colorado、アメリカ、80218
        • 募集
        • Colorado Blood Cancer Institute
    • Connecticut
      • New Haven、Connecticut、アメリカ、06510
        • 募集
        • Yale University School Of Medicine
    • New York
      • New York、New York、アメリカ、10029
        • 募集
        • Icahn School of Medicine at Mt. Sinai
      • Rochester、New York、アメリカ、14642
        • 募集
        • University of Rochester Medical Center
    • North Carolina
      • Durham、North Carolina、アメリカ、27705
        • 募集
        • Duke University Medical Center
    • Ohio
      • Cleveland、Ohio、アメリカ、44106
        • 募集
        • University Hospitals Cleveland Medical Center
    • Virginia
      • Richmond、Virginia、アメリカ、23298
        • 募集
        • Virginia Commonwealth University - Massey Cancer Center
    • Washington
      • Seattle、Washington、アメリカ、98109
        • 募集
        • University of Washington
      • Belfast、イギリス、BT9 7AB
        • 募集
        • Belfast City Hospital
      • Colchester、イギリス、CO4 5JL
        • 募集
        • Colchester Hospital University NHS
      • Eastbourne、イギリス、BN21 2UD
        • 募集
        • Eastbourne District General Hospital
      • Liverpool、イギリス、L7 8YA
        • 募集
        • The Clatterbridge Cancer Centre
      • London、イギリス、W12 0HS
        • 募集
        • Hammersmith Hospital
      • London、イギリス、NW1 2BU
        • 募集
        • University College London Hospitals
      • Manchester、イギリス、M20 4BX
        • 募集
        • The Christie NHS Foundation Trust Christie Hospital
      • Newcastle upon Tyne、イギリス、NE7 7DN
        • 完了
        • Newcastle Freeman Hospital
      • Amsterdam、オランダ、1081 HV
        • 募集
        • VUMC Amsterdam
      • Dordrecht、オランダ、3318 AT
        • 募集
        • Albert Schweitzer Ziekenhuis
      • Rotterdam、オランダ、3015 CN
        • 募集
        • Erasmus MC
      • Badalona、スペイン、08916
        • 募集
        • Hosp. Univ. Germans Trias I Pujol
      • Barcelona、スペイン、08036
        • 募集
        • Hosp Clinic de Barcelona
      • El Palmar、スペイン、30120
        • 募集
        • Hosp. Univ. Virgen de La Arrixaca
      • Jerez de la Frontera、スペイン、11407
        • 募集
        • Hosp. de Jerez de La Frontera
      • Madrid、スペイン、28034
        • 募集
        • Hosp. Univ. Ramon Y Cajal
      • Madrid、スペイン、28041
        • 募集
        • Hosp. Univ. 12 de Octubre
      • Pozuelo de Alarcón、スペイン、28223
        • 募集
        • Hosp. Quiron Madrid Pozuelo
      • Salamanca、スペイン、37007
        • 募集
        • Hosp Clinico Univ de Salamanca
      • Brasília、ブラジル、70390-140
        • 募集
        • IDOR - Regional Brasilia
      • Caxias do Sul、ブラジル、95070 560
        • 募集
        • Fundacao Universidade de Caxias do Sul
      • Curitiba、ブラジル、81520-060
        • 募集
        • Hospital Erasto Gaertner- Liga Paranaense de Combate ao Cancer
      • Salvador、ブラジル、41253-190
        • 募集
        • IDOR - Regional Bahia
      • São Paulo、ブラジル、04537 081
        • 募集
        • Clinica Medica Sao Germano LTDA
      • São Paulo、ブラジル、01401 002
        • 募集
        • IDOR - Regional Sao Paulo
      • San Juan、プエルトリコ、00918
        • 募集
        • Hospital Espanol Auxilio Mutuo Auxilio Mutuo Cancer Center
      • Seoul、韓国、03080
        • 募集
        • Seoul National University Hospital
      • Seoul、韓国、06591
        • 募集
        • The Catholic University of Korea Seoul St Mary s Hospital
      • Seoul、韓国、135-230
        • 募集
        • Samsung Medical Center

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Multiple myeloma (MM) according to IMWG diagnostic criteria
  • Were triple-class exposed (received prior treatment with a PI, an IMiD, and anti CD38 mAb)
  • Documented evidence of progressive disease based on investigator's determination of response by IMWG criteria on or after their last regimen
  • Have an Eastern Cooperative Oncology Group-performance status (ECOG-PS) of 0 or 1 at screening. Participants with ECOG-PS 2 or 3 are eligible for the study if the ECOG-PS score is related to stable physical limitations (e.g., wheelchair-bound due to prior spinal cord injury) and not related to multiple myeloma or associated therapy
  • Be willing and able to adhere to the lifestyle restrictions specified in the protocol

Exclusion Criteria:

  • Contraindications or life-threatening known allergies, hypersensitivity, or intolerance to any study drug or its excipients
  • Stroke, transient ischemic attack, or seizure within 6 months prior to screening
  • Any of the following within 6 months prior to the first dose of study treatment: severe or unstable angina, myocardial infarction; major thromboembolytic event (e.g., pulmonary embolism, cerebrovascular accident), clinically significant ventricular arrythmia or heart failure New York Heart Association functional classification Class III or IV. Uncomplicated deep vein thrombosis is not considered exclusionary
  • Major surgery or had significant traumatic injury within 2 weeks prior to the start of administration of study treatment, or will not have fully recovered from surgery, or has major surgery planned during the time the participant is expected to be treated in the study or within 2 weeks after administration of the last dose of study treatment
  • A WETT score indicating severe dysgeusia at screening and confirmed prior to randomization. Also unresolved/severe dysgeusia referred by the participant or a finding in the physical examination/oral cavity inspection. Some examples include leukoplakia, prior mouth cancers, extensive dental caries, severe periodontitis, active oral infections, candidiasis, parotic gland removal, or radiotherapy with resultant xerostomia

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:Cohort A: Talquetamab

Participants with relapsed or refractory multiple myeloma (RRMM) who are triple-class exposed (previously exposed to at least 1 proteasome inhibitor [PI], 1 immunomodulatory drug(s) [IMiD]), and an anti-CD38 monoclonal antibody [mAb]) will be treated with talquetamab subcutaneously until disease progression, death, unacceptable toxicity, withdrawal of consent, discontinuation of talquetamab, or end of study, whichever occurs first.

Talquetamab will be administered subcutaneously.

他の名前:
  • CD3xGPRC5D
実験的:Cohort B: Prophylaxis A and Talquetamab

Participants with RRMM who are triple-class exposed (previously exposed to at least 1 PI, 1 IMiD, and an anti-CD38 mAb) will receive prophylaxis A along with talquetamab therapy. Participants will start the assigned prophylaxis 7 days before starting talquetamab treatment. After step-up dosing of talquetamab therapy, participants will be treated with talquetamab with prophylaxes for up to 12 months during prophylaxis treatment phase (if there are clinical benefits prophylaxis treatment can continue beyond 12 months, at the treating physician's discretion, after consultation with sponsor). The Talquetamab treatment phase will continue from Cycle 1 Day 1 (C1D1) until disease progression, death, unacceptable toxicity, withdrawal of consent, discontinuation of talquetamab, or end of study, whichever occurs first.

Talquetamab will be administered subcutaneously.

他の名前:
  • CD3xGPRC5D

Prophylaxis A will be administered orally.

実験的:Cohort C: Prophylaxis B and Talquetamab

Participants with RRMM who are triple-class exposed (previously exposed to at least 1 PI, 1 IMiD, and an anti-CD38 mAb) will receive prophylaxis B along with talquetamab therapy. Participants will start the assigned prophylaxis 7 days before starting talquetamab treatment. After step-up dosing of talquetamab therapy, participants will be treated with talquetamab with prophylaxes for up to 12 months during prophylaxis treatment phase (if there are clinical benefits prophylaxis treatment can continue beyond 12 months, at the treating physician's discretion, after consultation with sponsor). The Talquetamab treatment phase will continue from C1D1 until disease progression, death, unacceptable toxicity, withdrawal of consent, discontinuation of talquetamab, or end of study, whichever occurs first.

Talquetamab will be administered subcutaneously.

他の名前:
  • CD3xGPRC5D

Prophylaxis B will be administered orally.

実験的:Cohort D: Prophylaxis C and Talquetamab

Participants with RRMM who are triple-class exposed (previously exposed to at least 1 PI, 1 IMiD, and an anti-CD38 mAb) will receive prophylaxis C along with talquetamab therapy. Participants will start the assigned prophylaxis 7 days before starting talquetamab treatment. After step-up dosing of talquetamab therapy, participants will be treated with talquetamab with prophylaxes for up to 12 months during prophylaxis treatment phase (if there are clinical benefits prophylaxis treatment can continue beyond 12 months, at the treating physician's discretion, after consultation with sponsor). The Talquetamab treatment phase will continue from C1D1 until disease progression, death, unacceptable toxicity, withdrawal of consent, discontinuation of talquetamab, or end of study, whichever occurs first.

Talquetamab will be administered subcutaneously.

他の名前:
  • CD3xGPRC5D

Prophylaxis C will be administered orally.

実験的:Cohort E: Prophylaxis D and Talquetamab

Participants with RRMM who are triple-class exposed (previously exposed to at least 1 PI, 1 IMiD, and an anti-CD38 mAb) will receive prophylaxis D along with talquetamab therapy. Participants will start the assigned prophylaxis 1 day before starting talquetamab treatment. After step-up dosing of talquetamab therapy, participants will be treated with talquetamab with prophylaxes for up to 12 months during prophylaxis treatment phase (if there are clinical benefits prophylaxis treatment can continue beyond 12 months, at the treating physician's discretion, after consultation with sponsor). The Talquetamab treatment phase will continue from C1D1 until disease progression, death, unacceptable toxicity, withdrawal of consent, discontinuation of talquetamab, or end of study, whichever occurs first.

Talquetamab will be administered subcutaneously.

他の名前:
  • CD3xGPRC5D

Prophylaxis D will be administered topically.

実験的:Cohort F: Ramantamig

Participants with RRMM who are triple-class exposed (previously exposed to at least 1 PI, 1 IMiD, and an anti-CD38 mAb) will receive single step-up dose of ramantamig subcutaneously followed by the treatment dose until disease progression, death, unacceptable toxicity, withdrawal of consent, discontinuation of ramantamig, or end of study, whichever occurs first.

Ramantamig will be administered subcutaneously.

他の名前:
  • BCMAxGPRC5DxCD3

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Percentage of Participants With Occurrence of Dysgeusia as Assessed by the Total Waterless Empirical Taste Test (WETT) Testing Score During the Prophylaxis Treatment Phase
時間枠:Up to 12 months

Dysgeusia is defined as total WETT score of 25th percentile or below according to the Normative WETT-SA53 percentile table. Taste assessment will be performed using taste strips (WETT). Four concentrations (4=lowest concentration, 1=highest concentration) will be used for each taste quality: sweet, sour, salty, bitter, and umami. Each test kit contains 53 taste strips distributed in 4 packs; and each taste strip is numbered (1 through 53). Participants will use each strip sequentially and record the flavor on a score card provided. The test will result in a maximum (that is, best) total score of 53. The score will be graded by a qualified site staff into a normative percentile score using a provided chart.

Up to 12 months
Percentage of Participants With Occurrence of Severe Dysgeusia During the Prophylaxis Treatment Phase
時間枠:Up to 12 months

Severe Dysgeusia is defined as a total WETT score of 10th percentile or below according to the normative WETT-SA53 percentile table. Taste assessment will be performed using taste strips (WETT). Four concentrations (4=lowest concentration, 1=highest concentration) will be used for each taste quality: sweet, sour, salty, bitter, and umami. Each test kit contains 53 taste strips distributed in 4 packs; and each taste strip is numbered (1 through 53). Participants will use each strip sequentially and record the flavor on a score card provided. The test will result in a maximum (that is, best) total score of 53. The score will be graded by a qualified site staff into a normative percentile score using a provided chart.

Up to 12 months
Time to the First Onset of Severe Dysgeusia During the Prophylaxis Treatment Phase
時間枠:Up to 12 months

Time to the first onset of severe dysgeusia is defined as time from the first dose date of talquetamab to the first onset date of severe dysgeusia according to the total WETT score. For participants without severe dysgeusia, time to the first onset will be censored. Taste assessment will be performed using taste strips (WETT). Four concentrations (4=lowest concentration, 1=highest concentration) will be used for each taste quality: sweet, sour, salty, bitter, and umami. Each test kit contains 53 taste strips distributed in 4 packs; and each taste strip is numbered (1 through 53). Participants will use each strip sequentially and record the flavor on a score card provided. The test will result in a maximum (that is, best) total score of 53. The score will be graded by a qualified site staff into a normative percentile score using a provided chart.

Up to 12 months
Percentage of Participants Who Report Resolution/Improvement of Dysgeusia During the Prophylaxis Treatment Phase
時間枠:End of Month 3

Resolution/improvement is defined as 2 potential scenarios: 1) A dysgeusia downgraded to dysgeusia-free, that is (i.e.,) total WETT score of 25th percentile or below at visits prior to the end of month 3 becomes total WETT score above 25th percentile at the end of month 3. 2) Severe dysgeusia downgraded to non-severe dysgeusia, i.e., total WETT score of 10th percentile or below prior to the end of month 3 becomes total WETT score above 10th percentile at the end of month 3. Taste assessment will be performed using taste strips (WETT). Four concentrations will be used for each taste quality: sweet, sour, salty, bitter, & umami. Each test kit contains 53 taste strips; numbered (1 through 53). Participants will use each strip sequentially and record flavor on score card provided. Test will result in maximum (i.e., best) total score of 53. Score will be graded by qualified staff into normative percentile score using provided chart.

End of Month 3
Percentage of Participants Who Report Resolution/Improvement of Dysgeusia During the Prophylaxis Treatment Phase
時間枠:End of Month 7

Resolution/improvement is defined as 2 potential scenarios: 1) A dysgeusia downgraded to dysgeusia-free, that is (i.e.,) total WETT score of 25th percentile or below at visits prior to the end of month 7 becomes total WETT score above 25th percentile at the end of month 7. 2) Severe dysgeusia downgraded to non-severe dysgeusia, i.e., total WETT score of 10th percentile or below prior to the end of month 7 becomes total WETT score above 10th percentile at the end of month 7. Taste assessment will be performed using taste strips (WETT). Four concentrations will be used for each taste quality: sweet, sour, salty, bitter, & umami. Each test kit contains 53 taste strips; numbered (1 through 53). Participants will use each strip sequentially and record flavor on score card provided. Test will result in maximum (i.e., best) total score of 53. Score will be graded by qualified staff into normative percentile score using provided chart.

End of Month 7

二次結果の測定

結果測定
メジャーの説明
時間枠
Change From Baseline in WETT Testing Score Over Time
時間枠:Baseline up to 36 months

Taste assessment will be performed using taste strips (WETT). Four concentrations (4=lowest concentration, 1=highest concentration) will be used for each taste quality: sweet, sour, salty, bitter, and umami. Each test kit contains 53 taste strips distributed in 4 packs; and each taste strip is numbered (1 through 53). Participants will use each strip sequentially and record the flavor on a score card provided. The test will result in a maximum (that is, best) total score of 53.

Baseline up to 36 months
Percentage of Time with Dysgeusia During the Prophylaxis Treatment Phase
時間枠:Up to 12 months

Time with dysgeusia is defined as the accumulative days a participant had dysgeusia according to the total WETT score divided by the total days of talquetamab exposure. Taste assessment will be performed using taste strips (WETT). Four concentrations (4=lowest concentration, 1=highest concentration) will be used for each taste quality: sweet, sour, salty, bitter, and umami. Each test kit contains 53 taste strips distributed in 4 packs; and each taste strip is numbered (1 through 53). Participants will use each strip sequentially and record the flavor on a score card provided. The test will result in a maximum (that is, best) total score of 53. The score will be graded by a qualified site staff into a normative percentile score using a provided chart.

Up to 12 months
Percentage of Participants with Treatment-Emergent Oral Toxicities (Dysgeusia, Oral Mucositis, Dysphagia, and Xerostomia) During the Prophylaxis Treatment Phase
時間枠:Up to 12 months

Oral toxicity including dysgeusia, oral mucositis, dysphagia, and xerostomia will be graded (including Grade 0 for dysgeusia) based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 5.0. Severity has 5 grades based on CTCAE criteria: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening consequences; and Grade 5: Death.

Up to 12 months
Percentage of Participants with Treatment-Emergent Oral Toxicities (Dysgeusia, Oral Mucositis, Dysphagia, and Xerostomia) During the Study
時間枠:Up to 30 days after the last dose of study treatment (that is, approximately up to 36 months)

Oral toxicity including dysgeusia, oral mucositis, dysphagia, and xerostomia will be graded (including Grade 0 for dysgeusia) based on NCI-CTCAE, Version 5.0. Severity has 5 grades based on CTCAE criteria: Grade 1: Mild; Grade 2: Moderate; Grade 3: Severe; Grade 4: Life-threatening consequences; and Grade 5: Death.

Up to 30 days after the last dose of study treatment (that is, approximately up to 36 months)
Time to the First Onset of Treatment-Emergent Oral Toxicities (Dysgeusia, Oral Mucositis, Dysphagia, and Xerostomia)
時間枠:Up to 36 months

Time to the first onset of treatment-emergent dysgeusia, oral mucositis, dysphagia, or xerostomia, will be reported.

Up to 36 months
Duration of Treatment-emergent Oral Toxicities (Dysgeusia, Oral Mucositis, Dysphagia, and Xerostomia)
時間枠:Up to 36 months

Duration of treatment-emergent oral toxicities including dysgeusia, oral mucositis, dysphagia, and xerostomia will be reported in this outcome measure.

Up to 36 months
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 items (EORTC-QLQ-C30) Domains Scores Over Time
時間枠:From Baseline, up to 12 months (Cohorts A to E); up to 24 months (for Cohort F)

The EORTC-QLQ-C30 includes 30 items that make up 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 5 single symptom items (dyspnea, insomnia, appetite loss, constipation, and diarrhea) and a single impact item (financial difficulties). The recall period is 7 days, and responses are reported using verbal and numeric rating scales. The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. A high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status represents high health related quality of life (HRQoL), but a high score for a symptom scale/item represents a high level of symptomatology/problems.

From Baseline, up to 12 months (Cohorts A to E); up to 24 months (for Cohort F)
Change From Baseline in the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Oral Health (EORTC-QLQ-OH15) Domains Scores Over Time
時間枠:From Baseline, up to 12 months (Cohorts A to E); up to 24 months (for Cohort F)

The EORTC module QLQ-OH15 is a 15-item, well-accepted, and validated assessment tool focusing on oral problems and quality of life. The recall period for symptoms is 7 days and response options include 'not at all', "a little', 'quite a bit', and 'very much'. All of the items' measures range in score from 0 to 100. A high score for the symptom items represents a high level of symptomatology or problems.

From Baseline, up to 12 months (Cohorts A to E); up to 24 months (for Cohort F)
Percentage of Participants Reporting Oral Symptoms Using the Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
時間枠:Up to 12 months (Cohorts A to E); Up to 24 months (for Cohort F)

PRO-CTCAE is a patient-reported item custom survey used to evaluate symptomatic treatment-emergent adverse events in participants on cancer clinical trials. The PRO-CTCAE custom survey consists of 18 items. Responses are provided on a 5-point Likert scale that ranges from 0 to 4. The recall period for symptoms is 7 days. Higher scores indicating greater severity/impact.

Up to 12 months (Cohorts A to E); Up to 24 months (for Cohort F)
Percentage of Participants Reporting Oral Symptoms Using the Short Xerostomia Inventory (SXI) Score
時間枠:Up to 12 months (Cohorts A to E); Up to 24 months (for Cohort F)

SXI is a validated questionnaire that explores how the participant experiences dry mouth (xerostomia) with 5 questions extracted from the original XI. Respondents are asked to choose 1 of 5 responses ("1-Never; 2-Hardly ever; 3-Occasionally; 4-Fairly often; and 5-Very often") to specific statements referring to the preceding 4 weeks. Each individual's responses are scored and summed to give a single XI score. Higher scores represent more severe symptoms.

Up to 12 months (Cohorts A to E); Up to 24 months (for Cohort F)
Percentage of Participants Reporting Oral Symptoms Using the Epstein Taste Survey (ETS)
時間枠:Up to 12 months (Cohorts A to E); Up to 24 months (for Cohort F)

The Epstein Taste Survey (ETS) consists of 17 items PRO instrument, specific to taste and smell changes. The ETS was developed for use in participants with head and neck cancer. This instrument will be used to measure treatment-related symptoms associated with talquetamab.

Up to 12 months (Cohorts A to E); Up to 24 months (for Cohort F)
Percentage of Participants Reporting Oral Symptoms Using the Scale of Subjective Total Taste Acuity (STTA)
時間枠:Up to 12 months (Cohorts A to E); Up to 24 months (for Cohort F)

The STTA is a tool to assess the overall acuity of taste based on a 4-point scale, where 0 reflects no change and 4 represents almost complete loss of taste function. Higher score indicating severity.

Up to 12 months (Cohorts A to E); Up to 24 months (for Cohort F)
Change from Baseline in Body Weight Over Time
時間枠:From Baseline up to 36 months

Change from baseline in body weight will be reported.

From Baseline up to 36 months
Change from Baseline in Body Mass Index (BMI) Over Time
時間枠:From Baseline up to 36 months

Change from baseline in BMI will be reported.

From Baseline up to 36 months
Percentage of Participants With Dose Reductions, Interruptions, and Discontinuations For Talquetamab and Ramantamig
時間枠:Up to 12 months (Cohorts A to E); Up to 24 months (for Cohort F)

Percentage of participants with dose reductions, dose interruptions, and dose discontinuations will be reported.

Up to 12 months (Cohorts A to E); Up to 24 months (for Cohort F)
Change from Baseline in Smell Identification Test Score
時間枠:Baseline (Day 1 Cycle 1), Day 1 Cycle 2 (each cycle duration=28-days)

Smell identification testing will be performed using 4 booklets each containing 10 labels that will release a distinctive scent when scraped with a pencil. Participants will choose the appropriate scent from the associated options. The minimum possible score is a 0 and the maximum is a 40. A higher score indicates better smell/outcome.

Baseline (Day 1 Cycle 1), Day 1 Cycle 2 (each cycle duration=28-days)
Percentage of Participants With Overall Response Rate
時間枠:Up to 36 months

Overall response rate is defined as the participants with a partial response (PR) or better according to the International Myeloma Working Group (IMWG) criteria.

Up to 36 months
Percentage of Participants With Complete Response (CR) or Better Response
時間枠:Up to 36 months

CR or better response is defined as the participants who achieve a CR or better response according to the IMWG criteria.

Up to 36 months
Percentage of Participants With Very Good Partial Response (VGPR) or Better Response
時間枠:Up to 36 months

VGPR or better response is defined as the percentage of participants who achieve a VGPR or better response according to the IMWG criteria.

Up to 36 months
Duration of Response (DOR)
時間枠:Up to 36 months

Duration of response is defined as time from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease, as defined in the IMWG criteria, or death due to any reason, whichever occurs first.

Up to 36 months
Time to Response (TTR)
時間枠:Up to 36 months

Time to response is defined as the time between date of first dose of talquetamab or ramantamig and the first efficacy evaluation at which the participant has met all criteria for PR or better.

Up to 36 months
Progression-free Survival (PFS)
時間枠:Up to 36 months

PFS is defined as the time from the date of first dose of talquetamab or ramantamig to the date of first documented disease progression, as defined in the IMWG criteria, or death due to any cause, whichever occurs first.

Up to 36 months
Number of Participants with Treatment-emergent Adverse Event (TEAEs)
時間枠:Up to 36 months

An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Any AE occurring at or after the initial administration of study treatment through the day of last dose plus 30 days, or if beyond 30 days from last dose but is study treatment-related, is considered to be treatment-emergent.

Up to 36 months

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディディレクター:Janssen Research & Development, LLC Clinical Trial、Janssen Research & Development, LLC

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2024年8月26日

一次修了 (推定)

2030年5月30日

研究の完了 (推定)

2030年5月30日

試験登録日

最初に提出

2024年7月8日

QC基準を満たした最初の提出物

2024年7月8日

最初の投稿 (実際)

2024年7月15日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月25日

QC基準を満たした最後の更新が送信されました

2026年9月24日

最終確認日

2026年9月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する